169 terminated. 169 Phase 2, 23 Phase 1, 21 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 169 | Terminated 169 |
| Phase 1 | 23 | Terminated 23 |
| Phase 3 | 21 | Terminated 21 |
Follow Gastroenteritis: new trials by email Literature Review of Gastroenteritis trials Research Report on Gastroenteritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS) balinatunfib, balinatunfib-matching placebo - Colitis Ulcerative, Crohn's Disease | Phase 2 | Terminated | Sanofi | 7 | 2026-05-19 | 2026-10-22 |
| A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis SAR441566, SAR441566 matching Placebo - Colitis Ulcerative | Phase 2 | Terminated | Sanofi | 170 | 2025-03-28 | 2026-10-21 |
| A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. SAR441566, SAR441566 matching Placebo - Crohn's Disease | Phase 2 | Terminated | Sanofi | 105 | 2024-12-10 | 2026-10-13 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC) Vixarelimab, Placebo - Ulcerative Colitis | Phase 2 | Terminated | Genentech, Inc. | 79 | 2024-05-01 | 2026-02-24 |
| Study of ExoFlo for the Treatment of Perianal Fistulas ExoFlo, Local injection of normal saline - Perianal Fistula, Crohn's Disease | Phase 1 / Phase 2 | Terminated | Direct Biologics, LLC | 5 | 2023-08-28 | 2026-08-11 |
| A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy Ozanimod - Crohn Disease | Phase 2 / Phase 3 | Terminated | Bristol-Myers Squibb | 5 | 2023-08-22 | 2025-04-22 |
| VE202 in Patients With Mild-to-Moderate Ulcerative Colitis VE202, Vancomycin Oral Capsule, VE202 Placebo - Ulcerative Colitis, Colitis, Ulcerative | Phase 2 | Terminated | Vedanta Biosciences, Inc. | 114 | 2023-05-08 | 2025-12-17 |
| Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis Efavaleukin alfa, Placebo - Ulcerative Colitis | Phase 2 | Terminated | Amgen | 25 | 2023-04-28 | 2025-10-15 |
| Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis NX-13 250mg, NX-13 750mg, NX-13 Placebo - Ulcerative Colitis | Phase 2 | Terminated | AbbVie | 81 | 2023-04-24 | 2026-06-15 |
| Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant Xylitol, Placebo - Allogeneic Stem Cell Transplantation | Phase 2 | Terminated | Children's Hospital Medical Center, Cincinnati | 256 | 2023-04-04 | 2026-11-02 |
| VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease VTX958, VTX958 Placebo - Crohn Disease | Phase 2 | Terminated | Ventyx Biosciences, Inc | 107 | 2023-01-25 | 2025-07-03 |
| Clinical Trial to Evaluate if the Laparoscopic Administration of Cells Derived From the Fatty Tissue Can Improve the Inflammatory Stenosis in Patient With Crohn's Disease Adipose derived allogenic mesenchymal stem cells (adAMSC) - Stenosis; Bowel, Crohn Disease | Phase 1 / Phase 2 | Terminated | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 2 | 2022-10-24 | 2025-03-20 |
| Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy Ranolazine, Placebo - Crohn's Disease, Inflammatory Bowel Disease | Phase 2 | Terminated | Vanderbilt University Medical Center | 4 | 2022-10-18 | 2025-02-06 |
| Efficacy and Safety of Two Doses of HIL-214 in Children HIL-214, Placebo - Gastroenteritis | Phase 2 / Phase 3 | Terminated | HilleVax | 3084 | 2022-04-28 | 2025-07-10 |
| Efficacy of Liraglutide Therapy in Patients With IPAA Liraglutide Pen Injector, Placebo Pen Injector - Pouchitis, Irritable Pouch Syndrome | Phase 2 | Terminated | University of North Carolina, Chapel Hill | 8 | 2022-03-22 | 2024-07-23 |
| Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis SPH3127, Placebo - Ulcerative Colitis | Phase 2 | Terminated | Shanghai Pharma Biotherapeutics USA Inc. | 3 | 2022-03-21 | 2025-06-26 |
| Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally., Itraconazole's matching placebo 400 mg/day and terbinafine's matching placebo 500 mg/day administered orally. - Crohn's Disease, Inflammatory Bowel Diseases | Phase 2 | Terminated | Montreal Heart Institute | 16 | 2022-02-22 | 2024-05-30 |
| Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis Efavaleukin alfa, Placebo - Ulcerative Colitis | Phase 2 | Terminated | Amgen | 221 | 2022-01-31 | 2026-01-13 |
| A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease ABBV-154, Placebo - Crohn's Disease | Phase 2 | Terminated | AbbVie | 176 | 2022-01-31 | 2024-10-03 |
| Protonix Treatment of Maintenance of Healing in Pediatric Participants Aged 1-11 Years and 12-17 Years Full dose Pantoprazole plus matching placebo, Half Dose Pantoprazole plus matching placebo - Esophagitis | Phase 2 | Terminated | Pfizer | 43 | 2022-01-13 | 2026-06-15 |
Showing 20 of 169. Sign in to see all of them.
Crohn Disease (71) · Colitis, Ulcerative (61) · Inflammatory Bowel Diseases (31) · Mucositis (11) · Pouchitis (6) · Diarrhea (4) · Eosinophilic Esophagitis (4) · Esophagitis (4) · Inflammation (4) · Lymphoma, Follicular (4) · Colitis (3) · Enterocolitis, Necrotizing (3) · Fistula (3) · Gastrointestinal Diseases (3)
Digestive System Diseases (167) · Gastrointestinal Diseases (166) · Intestinal Diseases (143) · Inflammatory Bowel Diseases (104) · Colonic Diseases (63) · Colitis (59) · Pathological Conditions, Signs and Symptoms (21) · Pathologic Processes (14) · Immune System Diseases (12) · Mouth Diseases (11) · Stomatognathic Diseases (11) · Neoplasms (10) · Hemic and Lymphatic Diseases (9) · Neoplasms by Histologic Type (9)
Budesonide (3) · Metronidazole (3) · sargramostim (3) · visilizumab (3) · Adalimumab (2) · Aminosalicylic Acid (2) · Azathioprine (2) · Ciprofloxacin (2) · Cisplatin (2) · Fecal Microbiota Transplantation (2) · Radiation (2) · Radiotherapy (2) · Rifaximin (2) · Standard of Care (2) · andecaliximab (2)
Sanofi (5) · Amgen (4) · AstraZeneca (4) · Novartis Pharmaceuticals (4) · Anthony Lembo (3) · Boehringer Ingelheim (3) · Bristol-Myers Squibb (3) · Genzyme, a Sanofi Company (3) · Gilead Sciences (3) · Mayo Clinic (3) · Nationwide Children's Hospital (3) · Pfizer (3) · Theravance Biopharma (3) · University of Maryland, Baltimore (3) · University of North Carolina, Chapel Hill (3)
United States (117) · Canada (42) · Germany (42) · Poland (42) · Italy (37) · France (33) · Hungary (31) · Australia (28) · Belgium (27) · Czechia (27) · United Kingdom (26) · Netherlands (25) · Israel (24) · Spain (23) · Ukraine (23)
Amy Lightner, MD (4) · Kathy Bohannon (3) · Hans Herfarth, MD, PhD (2) · Karen L Kotloff, M.D. (2) · Katsuhisa Saito (2) · Miles H Hassell, MD (2)
PMID 18829790, PMID 19302707, PMID 20947884, PMID 21453880, PMID 22595313, PMID 24237037, PMID 25926532, PMID 26119226, PMID 29846530, PMID 31982148, PMID 33831327, PMID 33871807, PMID 34474038, PMID 35014040, PMID 35614292, PMID 36322714, PMID 36725090, PMID 37137672, PMID 37323059, PMID 38283244, PMID 38668926, PMID 39575597, PMID 39791563, PMID 39793589, PMID 41342324, PMID 41684726, PMID 42782131
2017 (7), 2018 (6), 2019 (6), 2014 (3), 2015 (2), 2023 (2), 2025 (2), 1UG3DE030401-01 (1), 2005 (1), 2008 (1), 2016 (1), P30CA015704 (1), U01DK060083 (1), UL1RR024150 (1)